CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Swiss biotech firm Molecular Partners to cut nearly half of workforce

By Reuters News

ZURICH, Oct 29 (Reuters) - Switzerland's Molecular Partners MOLN.S is cutting its workforce nearly in half, it said on Thursday, as it aims to narrow its focus on the booming field of radiotherapeutic medicines.

The clinical-stage biotech company, which has partnered with pharma giant Novartis NOVN.S and American AbbVie ABBV.N, is set to reduce its employee headcount by up to 44%, or up to 55 people.

  • Emerging clinical data for its lead radiotherapeutic drug candidate encouraged company transformation with focus on targeted radiotherapy, CEO Patrick Amstutz said in a statement

  • The reduction is expected be completed by the second quarter of 2027 and the related costs set to come into effect in the second half of the same year, Molecular Partners said

  • Previously announced timelines on clinical assets stand, the company said

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk